Danderyds Sjukhus AB
- Address
- lock Available on a paid plan
Renal & Immune‑Mediated Disorders
The department focuses on immune‑mediated kidney diseases such as IgA nephropathy, C3 glomerulopathy, focal segmental glomerulosclerosis and related proteinuric conditions, aiming to test new agents that preserve renal function and lower protein loss.
- Strategies to reduce proteinuria
- Complement pathway inhibition
- Oral therapies for chronic kidney disease progression
Danderyds Sjukhus AB supports over 50 active studies with 40 investigators, reflecting a strong commitment to advancing renal health.
Cardiovascular & Heart Failure Research
Investigations target major cardiovascular conditions including heart failure with preserved or reduced ejection fraction, atrial fibrillation, acute myocardial infarction and resistant hypertension, evaluating novel drugs and combination regimens to lower mortality and hospitalisation.
- SGLT2 inhibitor‑based combination therapies
- New oral agents for blood pressure control
- Anticoagulation alternatives for patients unsuitable for standard therapy
The site’s multidisciplinary team collaborates across cardiology and nephrology to improve outcomes for high‑risk patients.
Inflammatory Bowel Disease
Clinical work in Crohn’s disease and ulcerative colitis explores biologic and small‑molecule treatments designed to achieve clinical remission, endoscopic healing, and long‑term disease control.
- Maintenance therapy optimization
- Endoscopic response as a trial endpoint
- Combination of vedolizumab with upadacitinib
Research also includes primary sclerosing cholangitis, linking liver and gut inflammation in a comprehensive IBD program.
Infectious Disease Research
The unit conducts studies on viral and bacterial threats such as COVID‑19, chronic hepatitis D, tick‑borne encephalitis and severe viral lung infections, testing antivirals, immunoglobulin adjuncts and vaccine‑related outcomes.
- Antiviral efficacy and safety
- Immunoglobulin therapy for immunocompromised hosts
- Biomarker‑driven assessment of viral injury
These trials contribute to global efforts to improve infectious disease management and preparedness.
Orthopedic & Surgical Infection Prevention
Research on prosthetic joint infection and hip arthroplasty evaluates antibiotic‑impregnated bone grafts and analgesic techniques to reduce postoperative infection rates and enhance recovery.
- Bone graft infection control strategies
- Comparison of intrathecal morphine vs epidural analgesia
- Patient‑reported recovery quality after colorectal surgery
The surgical team integrates infection‑prevention science with modern operative practice.
Women’s Health & Reproductive Medicine
Studies address contraception after medical abortion, management of vulvovaginal atrophy, and the neurological impact of hormonal contraceptives, seeking safer, more effective options for women’s reproductive health.
- Immediate intrauterine device insertion post‑abortion
- Selective estrogen receptor modulators for atrophy symptoms
- Brain structure and function effects of combined hormonal contraceptives
The department collaborates with obstetrics and endocrinology to optimize women's health outcomes.
Critical Care & Neurology
The Intensive Care Platform Trial (INCEPT) and stroke studies examine acute interventions for acute ischemic stroke and severe viral encephalitis, comparing early thrombolysis strategies and measuring neuronal injury biomarkers.
- Early thrombolysis in patients on factor Xa inhibitors
- Platform trial design for ICU interventions
- Neurofilament light chain as a marker of viral brain injury
These efforts aim to standardize care and improve survival in critically ill patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 19 therapeutic areas and 15 of 84 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 66 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
- 1Karolinska Institutet7active
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB8trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Danderyds Sjukhus AB
lock Showing 1 of 60 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM). | Kardigan Inc. | Phase IV | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 84 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 6 | Unknown | 2020-12-15 | 2025-04-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.